- Conditions
- Metastatic Colorectal Cancer
- Interventions
- PF-05212384, Irinotecan, Cetuximab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 25
- States / cities
- Bakersfield, California • Los Angeles, California • Northridge, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 921
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Cancer, Metastatic Cancer
- Interventions
- irinotecan hydrochloride, adjuvant therapy, conventional surgery, radiofrequency ablation
- Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Seattle, Washington
- Conditions
- Colorectal Cancer
- Interventions
- AZD6244, Irinotecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Palm Springs, California • Aurora, Colorado + 9 more
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Cancer of the Pancreas
- Interventions
- Zunsemetinib, mFOLFIRINOX
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Interventions
- oxaliplatin, irinotecan, leucovorin, 5-fluorouracil, capecitabine, radiation, surgery, gemcitabine
- Drug · Radiation · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 14
- States / cities
- La Jolla, California • Chicago, Illinois • Evanston, Illinois + 11 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Irinotecan liposome injection, Topotecan
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 22
- States / cities
- Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 17 more
- Conditions
- Esophageal Adenocarcinoma, Gastric Adenocarcinoma
- Interventions
- Nal-IRI, Oxaliplatin, 5-FU, Trastuzumab, Pembrolizumab, Nivolumab
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Advanced Solid Tumors, Cancer, Advanced Solid Malignancies
- Interventions
- AZD7762, Irinotecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Nashville, Tennessee
- Conditions
- Small Cell Lung Cancer, Extensive Stage Lung Cancer, Chemonaive
- Interventions
- Novel Drug Combination
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Marietta, Georgia
- Conditions
- Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor, Neuroblastoma, Hepatoblastoma, Germ Cell Tumor
- Interventions
- Vorinostat
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
- Interventions
- Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Magnetic Resonance Imaging, Nephrectomy, Patient Observation, Positron Emission Tomography, Ultrasound Imaging, Vincristine, X-Ray Imaging
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 1,656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 154
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 129 more
- Conditions
- Cancer, Neoplasms, Tumors, Refractory Solid Tumors, Recurrent Solid Tumors
- Interventions
- IT-141
- Drug
- Lead sponsor
- Intezyne Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Seattle, Washington
- Conditions
- Lymphomas, Tumors
- Interventions
- Irinotecan
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Pancreatic Cancer
- Interventions
- Oxaliplatin, Irinotecan, 5-FU, Gemcitabine, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer
- Interventions
- DEBIRI, LC Bead M1, TACE
- Drug · Device · Procedure
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Colon Cancer, Rectum Cancer
- Interventions
- Cetuximab, Irinotecan
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cholangiocarcinoma
- Interventions
- Not listed
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- modified FOLFIRINOX, Pentamidine 300 MG Injection
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Lung Neoplasms, Non-Small Cell Lung Cancer
- Interventions
- Irinotecan, Cisplatin
- Drug
- Lead sponsor
- Leo W. Jenkins Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer
- Interventions
- Onvansertib, FOLFIRI, Bevacizumab
- Drug
- Lead sponsor
- Cardiff Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 24 more
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Pediatric, Central Nervous System Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- RRx-001, Temozolomide, Irinotecan
- Drug
- Lead sponsor
- EpicentRx, Inc.
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neuroblastoma Recurrent
- Interventions
- Temozolomide, Irinotecan, hu14.18K322A, N803, Sargramostim
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- San Francisco, California • Aurora, Colorado • Ann Arbor, Michigan + 2 more
- Conditions
- Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Interventions
- Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Docetaxel, Gemcitabine, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Questionnaire Administration, Sacituzumab Govitecan
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 162
- States / cities
- Phoenix, Arizona • Irvine, California • Orange, California + 127 more
- Conditions
- Pancreatic Cancer
- Interventions
- FOLFIRINOX, Capecitabine, Short Course Radiation, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts